Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

• FEV1: pre dose and up to 3 hours post dose at selected timepoints [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
• Forced Vital Capacity: pre dose and up to 3 hours post dose at selected timepoints [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
• Peak Expiratory Flow Rates: pre dose morning and evening [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
• Number of puffs of rescue medication used per day [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
• St George's Respiratory Questionnaire at selected time points [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
• Mahler Dyspnea Indices at selected timepoints [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
• Patient's Global Rating at selected timepoints [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
• COPD Exacerbations [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
• Adverse Events [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
• Vital Signs: pre dose and up to 3 hours post dose at selected timepoints [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
• Routine blood chemistry, hematology and urinalysis at selected timepoints [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
• 12 Lead ECG and Holter Monitoring (patient subset) at selected timepoints [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]

The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.

• Drug: Olodaterol (BI 1744)
  Comparison of low and high doses on efficacy and safety in COPD patients
• Drug: Formoterol
  Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
• Drug: Placebo
  Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
• Drug: Placebo
  Placebo for comparison Formoterolon safety and efficacy in COPD patients

• Experimental: Olodaterol (BI 1744) Low
  Low dose inhaled orally once daily from the Respimat inhaler
  Intervention: Drug: Olodaterol (BI 1744)
• Experimental: Olodaterol (BI 1744) High
  High dose inhaled orally once daily from the Respimat inhaler
  Intervention: Drug: Olodaterol (BI 1744)
• Active Comparator: Formoterol 12mcg
  12mcg inhaled twice daily from the Aerolizer inhaler
  Intervention: Drug: Formoterol
• Placebo Comparator: Placebo
  Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
  Interventions:

  • Drug: Placebo
  • Drug: Placebo

Inclusion criteria:

1. All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:post-bronchodilator FEV1<80% of predicted normal (ECSC) and a post-bronchodilator FEV1/FVC <70% at Visit 1
2. Male or female patients, 40 years of age or older
3. Patients must be current or ex-smokers with a smoking history of more than 10 pack years:

Exclusion criteria:

1. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT >x2 ULN, SGPT >x2 ULN, bilirubin >x2 ULN or creatinine >x2 ULN
2. Patients with a history of asthma and/or total blood eosinophil count greater than 600/mm3
3. Patients with thyrotoxicosis, paroxysmal tachycardia (>100 beats per minute)
4. Patients with a history of myocardial infarction within 1 year of screening visit, unstable or life-threatening cardiac arrhythmia, hospitalization for heart failure within the past year, known active tuberculosis, a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years, life-threatening pulmonary obstruction, cystic fibrosis, clinically evident bronchiectasis, significant alcohol or drug abuse
5. Patients who have undergone thoracotomy with pulmonary resection
6. Patients being treated with oral beta-adrenergics or oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.
7. Patients who regularly use daytime oxygen therapy for more than one hour per day.
8. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program
9. Pregnant or nursing women
10. Women of childbearing potential not using two effective methods of birth control (one barrier and one non-barrier).